Market Overview

UPDATE: Jefferies Raises PT to $25 on Insulet Following Eros FDA Approval

Related PODD
Insulet Partners with Glooko as its Preferred Data Management Partner for OmniPod Patients and Healthcare Providers
MannKind's New Man In Charge

Jefferies reiterated its Buy rating on Insulet (NASDAQ: PODD) and increased its price target from $23 to $25.

Jefferies said, "Insulet announced approval of the Eros pod this morning, bringing a close an almost two year 510k approval process. Insulet estimates it will take 45-60 days to educate customers and scale up to a full launch, which puts the beginning of the transition from the legacy pod to Eros in March. The company has stockpiled approximately 6-7 weeks of inventory with the current pod to enable a quick transition to Eros manufacturing."

Insulet closed at $21.85 on Friday.

Latest Ratings for PODD

Feb 2016BairdMaintainsNeutral
Nov 2015Morgan StanleyInitiates Coverage onEqual-weight
Aug 2015BenchmarkDowngradesBuyHold

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (PODD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters